STAT Plus: What does the latest twist in the Sarepta saga mean for the future of the FDA? We discuss

Earlier this week, the Food and Drug Administration released documents that reveal a schism within the agency regarding its approval of Vyondys 53, a medicine to treat boys with Duchenne muscular dystrophy made by Sarepta Therapeutics (SRPT).

The 2016 approval of the company’s first drug, Exondys 51, also for Duchenne muscular dystrophy, was controversial because it was approved on very early data. There was a voluble debate within the FDA over whether the treatment actually worked. Now, this saga seems to be repeating itself with a new drug.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: What does the latest twist in the Sarepta saga mean for the future of the FDA? We discuss »